Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €7.70 EUR
Change Today +0.108 / 1.42%
Volume 0.0
AFF On Other Exchanges
As of 7:55 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - €12.38
52 Week Low
10/15/14 - €5.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AFFYMETRIX INC (AFF)

affymetrix inc (AFF) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFF) Details

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line; products with clinical diagnostic and research applications, such as the CytoScan and OncoScan products; GeneTitan instrument system that runs genotyping and gene expression array plates; and QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers and other biological and health care manufacturers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta Plex assays for low to mid-plex experiments. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. It has collaboration agreement with Cytox Ltd. The company was founded in 1991 and is headquartered in Santa Clara, California.

1,200 Employees
Last Reported Date: 07/30/15
Founded in 1991

affymetrix inc (AFF) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $549.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $349.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $399.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $349.8K
Compensation as of Fiscal Year 2014.

affymetrix inc (AFF) Key Developments

Affymetrix Introduces Axiom Transplant Genotyping Array for Genomic Profiling of Immune-Related Markers

Affymetrix Inc. introduced Axiom® Transplant Genotyping Array, designed in collaboration with an international team of surgeons and scientists for research studies to improve transplantation success and individualize donor/patient selection and treatment. The array comprises 780,000 markers, including over 30,000 variants that may contribute to transplant rejection or other complications. Researchers will also find the array useful in the study of immunology, disease and drug treatments; meta-analyses may be conducted, combining data with other genotype databases such as the UK Biobank cohort, a collection of more than 500,000 volunteers genotyped using the Affymetrix UK Biobank Axiom Array. Axiom Transplant Genotyping Array was developed and tested by the International Genetics and Translational Research in Transplantation Network (iGeneTRAiN [2]), co-led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

Green Super Rice Project and Bill & Melinda Gates Foundation Selects Affymetrix Axiom Genotyping Platform for Developing New Rice Varieties

Affymetrix Inc. announced that it has been selected as the genotyping supplier by the Green Super Rice project coordinated by the Chinese Academy of Agricultural Sciences as part of their effort to develop, within the next three years, at least fifteen new rice varieties and deliver them to small-hold farmers in 16 countries in Africa and Asia, including China.

Affymetrix Inc. Eyeing Acquisitions

Affymetrix Inc. (NasdaqGS:AFFX) is seeking acquisitions. Gavin Wood, Executive Vice President and Chief Financial Officer of Affymetrix said that their strengthened balance sheet will allow them make tuck-in acquisitions within core verticals.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFF:GR €7.70 EUR +0.108

AFF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $19.59 USD +0.05
Luminex Corp $17.90 USD +0.26
Pacific Biosciences of California Inc $7.51 USD -0.29
Sequenom Inc $2.10 USD +0.07
Takara Bio Inc ¥1,230 JPY +53.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AFF Industry Range
Price/Earnings 39.7x
Price/Sales 1.9x
Price/Book 2.1x
Price/Cash Flow 37.0x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at